Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > RS
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(66)
•••
Comment by endpntplayon Nov 30, 2020 11:45pm
165 Views
Post# 32007104

RE:RE:RE:RE:RS

RE:RE:RE:RE:RS
Pandora wrote:
endpntplay wrote:

Did any of those companies have a lead drug or technology that failed a clinical trial? 


By my count antibe hasn't failed one yet. Market confusion around safety killed them 4 years ago though. Hence, the dilution to stay afloat. Antibe is the real deal now. 



Actually Briacell (BCT) is in a partnership program with both Merck and Incyte using their drugs Keytruda & INCMGA00012. They are supposed to make a presentation on progress Dec. 9 - 11.
They also recently announced a collaboration with the National Cancer Institute recently. So they have been in the limelight but to no avail so far.

 Yeah took a look at their website not very impressive, and Merck hands out keytruda like candy for small bios to develop in combination. 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities